

Special Issue

Immunosuppressive Signaling Regulation in Cancer Development 2.0

Message from the Guest Editors

Over the past few decades, new conceptual and technical advances in immunology have led to novel discoveries between the immune system and tumors. In 2017, the immune checkpoint inhibitor pembrolizumab was approved to treat solid tumors with mismatch repair genes (MMR) and/or exhibit microsatellite instability (MSI). However, only a small number of cancer patients have the MMR mutations, and the benefits are yet to fully materialize in the context of solid tumor patients. Therefore, there is a significant unmet clinical need to unravel and target pathways that facilitate the emergence of resistant disease to immune surveillance breakthrough. The aim of this Special Issue is to gather emerging research in cancer immunology and immunometabolism and discover the underlying mechanisms of immune evasion in cancer immunotherapy.

Guest Editors

Prof. Dr. Demin Cai

College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China

Dr. Chengfei Liu

Department of Urologic Surgery, University of California at Davis, Sacramento, CA 95616, USA

Deadline for manuscript submissions

closed (29 February 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/160301

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).